Breaking News Instant updates and real-time market news.

SCHW

Charles Schwab

$41.62

1.34 (3.33%)

07:17
07/17/19
07/17
07:17
07/17/19
07:17

Charles Schwab net interest revenue risk underappreciated, says Deutsche Bank

While Charles Schwab's Q2 results were relatively in line with estimates, investors are underappreciating the downside risk to net interest revenue given the lower interest rate environment and the lack of growth in the company's balance sheet cash, Deutsche Bank analyst Brian Bedell tells investors in a research note. He sees the stock getting pressured on Friday during Schwab's business update, as he expects management to reemphasize a flat balance sheet this year along with an expectation for a net interest margin closer to 240 basis points versus a previous mid-240s expectation. Bedell lowered his price target for Charles Schwab to $41 from $43 and keeps a Hold rating on the name.

  • 19

    Jul

  • 27

    Oct

SCHW Charles Schwab
$41.62

1.34 (3.33%)

07/12/19
BOFA
07/12/19
DOWNGRADE
Target $43
BOFA
Neutral
Charles Schwab downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded Charles Schwab to Neutral from Buy with a $43 price target. The analyst sees more downside risk to estimates from a "tougher" margin and revenue outlook.
07/12/19
07/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Neutral from Buy at Citi. 2. Rexnord (RXN) was downgraded to Underperform from Buy at BofA/Merrill while Parker-Hannifin (PH) was downgraded to Neutral from Buy. 3. Instructure (INST) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Peterson saying his rating change "in no way reflects any incremental concerns about the company's strategic direction," but is entirely about his more cautious view on 2020 growth projections. 4. MSC Industrial (MSM) downgraded to Neutral from Buy at Northcoast with analyst Tom Hayes citing the company's report of weaker than expected organic sales growth and margin headwinds in Q3. 5. Charles Schwab (SCHW) was downgraded to Neutral from Buy at BofA/Merrill and to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/15/19
WELS
07/15/19
NO CHANGE
WELS
Wells says Schwab deal wouldn't be 'transformative,' but 'not insignificant'
After The Wall Street Journal reported that Charles Schwab is in talks to acquire the brokerage and wealth-management operations of USAA for roughly $2B, Wells Fargo analyst Christopher Harris noted that the deal is said to involve $100B of client assets, or approximately a bit under 3% of Schwab's total client assets. Given this size, he said the theoretical deal "would clearly not qualify as a transformative deal although is not insignificant." The analyst, who pointed out that the economics of this potential transaction are unknown, believes the shares are trading higher due to the potential for deal-related EPS accretion. Harris has a Market Perform rating on Charles Schwab shares.
07/15/19
GSCO
07/15/19
NO CHANGE
Target $44
GSCO
Buy
Charles Schwab deal report points to wealth management push, says Goldman Sachs
After The Wall Street Journal reported that Charles Schwab is in talks to acquire the brokerage and wealth-management operations of USAA for roughly $2B, Goldman Sachs analyst Will Nance said he takes no view on the likelihood of any transaction but he does expect that investors will focus on the strategic rationale of a larger push into wealth management and near term financial implications of any deal if one is announced. The article said that the potential deal would push Schwab further into wealth management, which would have implications for potential cost savings, which would likely be lower given the significant employee costs of a wealth platform, noted Nance. He keeps a Buy rating and $44 price target on Charles Schwab shares, which are up 25c, or 0.6%, to $40.38 in afternoon trading.

TODAY'S FREE FLY STORIES

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

07:32
10/22/19
10/22
07:32
10/22/19
07:32
Hot Stocks
Kimberly-Clark CEO says 'we delivered excellent third quarter results' »

CEO Mike Hsu said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CBIO

Catalyst Biosciences

$5.38

-0.03 (-0.55%)

07:32
10/22/19
10/22
07:32
10/22/19
07:32
Conference/Events
Catalyst Biosciences management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

07:31
10/22/19
10/22
07:31
10/22/19
07:31
Earnings
Kimberly-Clark raises FY19 adj. EPS view to $6.75-$6.90 from $6.65-$6.80 »

The company is now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

07:31
10/22/19
10/22
07:31
10/22/19
07:31
Earnings
Lockheed Martin reports Q3 EPS $5.66, consensus $5.02 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SIMO

Silicon Motion

$38.88

0.96 (2.53%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Initiation
Silicon Motion initiated  »

Silicon Motion initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

  • 09

    Dec

DCTH

Delcath Systems

$0.00

(0.00%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Hot Stocks
Delcath Systems announces postponement of reverse stock split »

Delcath Systems announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Earnings
Kimberly-Clark reports Q3 adjusted EPS $1.84, consensus $1.80 »

Reports Q3 revenue $4.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

EW

Edwards Lifesciences

$227.10

-0.39 (-0.17%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

SPXC

SPX Corporation

$41.39

0.365 (0.89%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Initiation
SPX Corporation initiated  »

Seaport Global starts SPX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

SE

Sea Limited

$27.24

0.265 (0.98%)

07:30
10/22/19
10/22
07:30
10/22/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
10/22/19
10/22
07:30
10/22/19
07:30
General news
Treasury Market Outlook: yields have richened »

Treasury Market Outlook:…

TNYBF

Tinley Beverage Company

$0.00

(0.00%)

07:29
10/22/19
10/22
07:29
10/22/19
07:29
Hot Stocks
Tinley Beverage Company to launch non-alcoholic, THC-free beverages »

The Tinley Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$235.25

-4.59 (-1.91%)

07:28
10/22/19
10/22
07:28
10/22/19
07:28
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 05

    Dec

FSCT

ForeScout

$28.73

3.27 (12.84%)

07:26
10/22/19
10/22
07:26
10/22/19
07:26
Hot Stocks
ForeScout joins global cyber security alliance for operational technology »

Forescout Technologiesy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 12

    Dec

CDNS

Cadence Design

$66.67

1.07 (1.63%)

07:26
10/22/19
10/22
07:26
10/22/19
07:26
Recommendations
Cadence Design analyst commentary  »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 19

    Nov

IBKC

Iberiabank

$74.64

1.97 (2.71%)

07:25
10/22/19
10/22
07:25
10/22/19
07:25
Downgrade
Iberiabank rating change  »

Iberiabank downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SGEN

Seattle Genetics

$100.86

13.44 (15.37%)

07:24
10/22/19
10/22
07:24
10/22/19
07:24
Recommendations
Seattle Genetics analyst commentary  »

Seattle Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 07

    Dec

EMHTF

Emerald Health Therapeutics

$0.00

(0.00%)

07:24
10/22/19
10/22
07:24
10/22/19
07:24
Hot Stocks
Emerald Health Therapeutics expands cannabis products to Nova Scotia »

Emerald Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$183.73

7.49 (4.25%)

07:23
10/22/19
10/22
07:23
10/22/19
07:23
Recommendations
Vertex analyst commentary  »

Vertex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Mar

ORTX

Orchard Therapeutics

$12.09

0.1 (0.83%)

07:22
10/22/19
10/22
07:22
10/22/19
07:22
Hot Stocks
Orchard Therapeutics 'on track' to submit MAA for MLD in 1H20 »

Orchard remains on track…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

BABA

Alibaba

$173.57

4.39 (2.59%)

07:22
10/22/19
10/22
07:22
10/22/19
07:22
Recommendations
Alibaba analyst commentary  »

Daiwa expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 19

    Nov

ORTX

Orchard Therapeutics

$12.09

0.1 (0.83%)

07:21
10/22/19
10/22
07:21
10/22/19
07:21
Hot Stocks
Orchard Therapeutics presents data from OTL-200 in patients with MLD »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SWI

SolarWinds

$19.05

0.22 (1.17%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Downgrade
SolarWinds rating change  »

SolarWinds downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CHTR

Charter

$438.01

-2.45 (-0.56%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Recommendations
Charter analyst commentary  »

Charter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NVCN

Neovasc

$3.72

0.17 (4.79%)

07:18
10/22/19
10/22
07:18
10/22/19
07:18
Hot Stocks
Neovasc announces multiple presentations featuring Neovasc Reducer »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.